Pacific Biosciences of California Inc (NASDAQ:PACB) does about 9.74M shares in volume on a normal day but saw 16879744 shares change hands in Friday trading. The company now has a market cap of 422.03M USD. Its current market price is $1.55, marking an increase of 6.16% compared to the previous close of $1.46. The 52 week high reached by this stock is $14.55 whilst the lowest price level in 52 weeks is $1.25.
Pacific Biosciences of California Inc (PACB) has a 20-day trading average at $3.0482 and the current price is -89.35% off the 52-week high compared with 24.00% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.2270 and its 200-day simple moving average is $8.0466. If we look at the stock’s price movements over the week, volatility stands at 23.33%, which decreases to 11.03% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 20.55 to suggest the stock is oversold.
The consensus objective for the share price is $5.50, suggesting that the stock has a potential upside of 71.82% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 18, 2024 when Goldman downgraded the stock to “Neutral” and issued a price target of between $7 and $2.50.
Pacific Biosciences of California Inc (PACB) stock is down -51.10% over the week and -59.42% over the past month. Its price is -84.20% year-to-date and -86.06% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -$0.31 below consensus estimates by -$0.03. PACB’s earnings per share are forecast to grow by 15.70% this year and 19.60% over next year. Expected sales for next quarter are $48.13 million, which analysts say will come at $206.57 million for the current fiscal year and next year at $295.33 million. In addition, estimates put the company’s current quarterly revenue at an average of $43.16 million.
To reach the target analysts have set, the stock logically needs to grow 71.82 percent from here.
The company has a return on investment of -18.87% and return on equity of -48.53%. The beta has a value of 2.02. Price to book ratio is 0.59 and price to sales ratio is 2.10.
